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The human proteome is a major source of therapeutic targets. Recent genetic association 
analyses of the plasma proteome enable systematic evaluation of the causal 
consequences of variation in plasma protein levels. Here we estimated the effects of 1,002 
proteins on 225 phenotypes using two-sample Mendelian randomization (MR) and 
colocalization. Of 413 associations supported by evidence from MR, 130 (31.5%) were not 
supported by results of colocalization analyses, suggesting that genetic confounding due 
to linkage disequilibrium (LD) is widespread in naïve phenome-wide association studies of 
proteins. Combining MR and colocalization evidence in cis-only analyses, we identified 
111 putatively causal effects between 65 proteins and 52 disease-related phenotypes 
(www.epigraphdb.org/pqtl/). Evaluation of data from historic drug development 
programs showed that target-indication pairs with MR and colocalization support were 
more likely to be approved, evidencing the value of this approach in identifying and 
prioritizing potential therapeutic targets. 




Despite increasing investment in research and development (R&D) in the pharmaceutical 
industry1, the rate of success for novel drugs continues to fall2. Lower success rates make 
new therapeutics more expensive, reducing availability of effective medicines and 
increasing healthcare costs. Indeed, only one in ten targets taken into clinical trials reaches 
approval2, with many showing lack of efficacy (~50%) or adverse safety profiles (~25%) in 
late stage clinical trials after many years of development3,4. For some diseases, such as 
Alzheimer’s disease, the failure rates are even higher5. 
Thus, early approaches to prioritize target-indication pairs that are more likely to be 
successful are much needed. It has previously been shown that target-indication pairs for 
which genetic associations link the target gene to related phenotypes are more likely to 
reach approval6. Consequently, systematically evaluating the genetic evidence in support of 
potential target-indication pairs is a potential strategy to prioritize development programs. 
While systematic genetic studies have evaluated the putative causal role of both methylome 
and transcriptome on diseases7,8, studies of the direct relevance of the proteome are in 
their infancy9,10. 
Plasma proteins play key roles in a range of biological processes and represent a 
major source of druggable targets11,12. Recently published genome-wide association studies 
(GWAS) of plasma proteins have identified 3,606 conditionally independent single 
nucleotide polymorphisms (SNPs) associated with 2,656 proteins (‘protein quantitative trait 
loci’, pQTL)9,13,14,15,16.  These genetic associations offer the opportunity to systematically test 
the causal effects of a large number of potential drug targets on the human disease 
phenome through Mendelian randomization (MR)17. In essence, MR exploits the random 
allocation of genetic variants at conception and their associations with disease risk factors 
to uncover causal relationships between human phenotypes, and has been described in 
detail previously18,19. 
For MR analyses of proteome, unlike more complex exposures, an intuitive way to 
categorize protein-associated variants is into cis-acting pQTLs located in the vicinity of the 
encoding gene (defined as ≤ 500 kb from the leading pQTL of the test protein in this study) 
and trans-acting pQTLs located outside this window. The cis-acting pQTLs are considered to 
have a higher biological prior and have been widely employed in relation to some phenome-
wide scans of drug targets such as CETP20 and IL6R21. Trans-acting pQTLs may operate via 
indirect mechanisms and are therefore more likely to be pleiotropic22, although they may 
support causal inference where they are likely to be non-pleiotropic. 
Here we pool and cross-validate pQTLs from five recently published GWAS and use 
them as instruments to systematically evaluate the causal role of 968 plasma proteins on 
the human phenome, including 153 diseases and 72 risk factors available in the MR-Base 
database23. Results of all analyses are available in an open online database 









Characterizing genetic instruments for proteins 
Figure 1 summarizes the genetic instrument selection and validation process. Briefly, we 
curated 3,606 pQTLs associated with 2,656 proteins from five GWAS9,13,14,15,16. After 
removing proteins and SNPs using criteria such as LD-pruning listed in Online Methods 
(Instrument selection), we retained 2,113 pQTLs for 1,699 proteins as instruments for the 
MR analysis (Supplementary Table 1). Among these instruments, we conducted further 
validation by categorizing them into three tiers based on their likely utility for MR analysis 
(Online Methods, Instrument validation): 1,064 instruments of 955 proteins with the 
highest relative level of reliability (tier 1); 62 instruments that exhibited SNP effect 
heterogeneity across studies (Supplementary Figs. 1 and 2), indicating uncertainty in the 
reliability of one or all instruments for a given protein (tier 2; Supplementary Tables 2 and 
3); and 987 non-specific instruments that were associated with more than five proteins (tier 
3). For the 263 tier 1 instruments associated with between two and five proteins, 68 of 
them influenced multiple proteins in the sample biological pathway and thus are likely to 
reflect vertical pleiotropy and remain valid instruments (Supplementary Note, 
Distinguishing vertical and horizontal pleiotropic instruments using biological pathway 
data)22.  
Among the 1,126 tier 1 and 2 instruments, 783 (69.5%) were cis-acting (within 500 
kb of the leading pQTL) and 343 were trans-acting. Of 1,002 proteins with a valid 
instrument, 765 had only a single cis or trans instrument, 66 were influenced by both cis and 
trans SNPs (Supplementary Table 4), and 153 had multiple conditionally distinct cis 
instruments (381 cis instruments shown in Supplementary Table 5).  
 
Estimated effects of plasma proteins on human phenotypes  
We undertook two-sample MR to systematically evaluate evidence for the causal effects of 
1,002 plasma proteins (with tier 1 and tier 2 instruments) on 153 diseases and 72 disease-
related risk factors (Supplementary Table 6 and Online Methods, Phenotype selection). 
Overall, we observed 413 protein-trait associations with MR evidence (P < 3.5 x 10-7 at a 
Bonferroni-corrected threshold) using either cis or trans instruments (or both for proteins 
with multiple instruments). 
Genetically filtering out predicted associations between proteins and phenotypes 
may indicate four explanations: causality, reverse causality, confounding by LD between the 
leading SNPs for proteins and phenotypes, or horizontal pleiotropy (Supplementary Fig. 3). 
Given these alternative explanations, we conducted a set of sensitivity analyses to establish 
whether the MR association reflects a causal effect of protein on phenotype: tests of 
reverse causality using bi-directional MR24 and MR Steiger filtering25,26; heterogeneity 
analyses for proteins with multiple instruments27, and colocalization analyses28 to 
investigate whether the genetic associations with both protein and phenotype shared the 
same causal variant (Fig. 1). To avoid unreliable inference from colocalization analysis due to 
the potential presence of multiple neighboring association signals, we also developed and 
performed pairwise conditional and colocalization analysis (PWCoCo) of all conditionally 
independent instruments against all conditionally independent association signals for the 
outcome phenotypes (Online Methods, Pairwise conditional and colocalization analysis; Fig. 
2). For this study, MR and colocalization were the two methods filtering reliable 
associations. After the colocalization analysis, 283 of the 413 protein-phenotype 
associations had profiles supportive of causality.  





Estimating protein effects on human phenotypes using cis pQTLs 
In the MR analyses using cis-pQTLs, we identified 111 putatively causal effects of 65 proteins 
on 52 phenotypes, with strong evidence of MR (P < 3.5 x 10-7) and colocalization (posterior 
probability > 80%; after applying PWCoCo) between the protein- and phenotype-associated 
signals (Fig. 3 and Supplementary Table 7). A further 69 potential associations had evidence 
from MR but did not have strong evidence of colocalization (posterior probability < 80%; 
Supplementary Table 8), highlighting the potential for confounding by LD and the 
importance of colocalization analyses in MR of proteins. Evidence of potentially causal 
effects supported by colocalization was identified across a range of disease categories, 
including anthropometric phenotypes and cardiovascular and autoimmune diseases 
(Supplementary Note, Disease areas of protein-trait associations), and our findings 
replicated some previous reported associations (Supplementary Note, MR results replicated 
previous findings). 
Of 437 proteins with tier 1 or tier 2 cis instruments from Sun et al.9 and Folkersen et 
al.14, 153 (35%) had multiple conditionally independent SNPs in the cis region identified by 
GCTA-COJO29 (Supplementary Table 5). We applied an MR model that takes into account 
the LD structure between conditionally independent SNPs in these cis regions30. In this 
analysis, we identified 10 additional associations that had not reached our Bonferroni 
corrected P-value threshold in the single-variant cis analysis. Generally, the MR estimates 
from the multi-cis MR analyses were consistent with the single-cis instrumented analyses 
(Supplementary Table 9).  
In regions with multiple cis instruments, 16 of the 111 top cis MR associations only 
showed evidence of colocalization after conducting PWCoCo analysis for both the proteins 
and the human phenotypes, where none was observed between marginal results 
(Supplementary Table 7). For example, interleukin 23 receptor (IL23R) had two 
conditionally independent cis instruments: rs11581607 and rs37623189. Conventional MR 
analysis combining both instruments showed a strong association of IL23R with Crohn’s 
disease (OR = 3.22, 95% CI = 2.93 to 3.53, P = 6.93 x 10-131; Supplementary Table 9b). There 
were four conditionally independent signals (conditional P < 1 x 10-7) predicted for Crohn’s 
disease in the same region (data from de Lange et al.31). In the marginal colocalization 
analyses, we observed no evidence of colocalization (Fig. 4 and Supplementary Fig. 4, 
colocalization probability = 0). After performing PWCoCo with each distinct signal in an 
iterative fashion, we observed compelling evidence of colocalization between IL23R and one 
of the Crohn’s disease signals for the top IL23R signal (rs11581607) (colocalization 
probability = 99.3%), but limited evidence for the second conditionally independent IL23R 
hit (rs7528804) (colocalization probability = 62.9%). Additionally, for haptoglobin, which 
showed MR evidence for LDL-cholesterol (LDL-C), there were two independent cis 
instruments. There was little evidence of colocalization between the two using marginal 
associations (colocalization probability = 0.0%). However, upon performing PWCoCo, we 
observed strong evidence of colocalization for both instruments (colocalization probabilities 
= 99%; Supplementary Table 10 and Supplementary Fig. 5). Both examples demonstrate 
the complexity of the associations in regions with multiple independent signals and the 
importance of applying appropriate colocalization methods in these regions. Of the 413 
associations with MR evidence (using cis and trans instruments), 283 (68.5%) also showed 
strong evidence of colocalization using either a traditional colocalization approach (260 
associations) or after applying PWCoCo (23 associations), suggesting that one third of the 




MR findings could be driven by genetic confounding by LD between pQTLs and other causal 
SNPs. 
Due to potential epitope-binding artefacts driven by protein-altering variants32, we 
also flag putatively causal links where the lead instrument is a protein-altering variant or is 
in high LD (r2 > 0.8) with one (Supplementary Tables 7 and 8 filtered by column 
“VEP_pQTL_Ldproxy” including missense, stop-lost/gained, start-lost/gained and splice-
altering variants).   
 
Using trans-pQTLs as additional instrument sources 
Trans pQTLs are more likely to influence targets though pleiotropic pathways. Among the 
1,316 trans instruments we identified from five studies, 73.5% were associated with more 
than five proteins, compared with 1.8 % of cis instruments (Supplementary Table 1). 
However, in the context of MR, including non-pleiotropic trans-pQTLs may increase the 
reliability of the protein-phenotype associations since (i) they will increase variance 
explained of the tested protein and increase power of the MR analysis; (ii) the causal 
estimate will not be reliant on a single locus, where multiple instruments exist; and (iii) 
further sensitivity analyses, such as heterogeneity test of MR estimates across multiple 
instruments, can be conducted. Therefore, we extended our MR analyses to include 343 
non-pleiotropic trans instruments (Supplementary Fig. 6). 
To utilize trans instruments, we first combined cis and trans instruments for 66 
proteins that had both cis and trans instruments (noted as cis + trans analysis). However, 
none reached our pre-defined Bonferroni-corrected threshold, and only two protein-
phenotype associations showed even suggestive evidence (P < 1 x 10-5) (Supplementary 
Table 11). Further, after including trans instruments, 17 of the cis-only signals were 
attenuated. Secondly, we performed trans-only MR analyses of 293 proteins and identified 
158 associations with 44 phenotypes that also had strong evidence (posterior probability > 
0.8) of colocalization (Supplementary Table 12). A further 54 trans-only MR associations did 
not have strong evidence of colocalization (Supplementary Table 13). 
Some of the trans analyses with MR and colocalization evidence suggest causal 
pathways that are confirmed by evidence from rare pathogenic variants or existing 
therapies. For example, although we had no cis instrument for Protein C (Inactivator Of 
Coagulation Factors Va And VIIIa) (PROC) (Supplementary Fig. 7a), we found evidence for a 
causal association between PROC levels and deep venous thrombosis (P = 1.27 x 10-10; 
colocalization probability > 0.9) using a trans pQTL, rs867186 (Supplementary Fig. 7b), 
which is a missense variant in PROCR33, the gene encoding the endothelial protein C 
receptor (EPCR). Individuals with mutations in PROC have protein C deficiency, a condition 
characterized by recurrent venous thrombosis for which replacement protein C is an 
effective therapy. 
From 47 proteins with multiple trans instruments, we identified four additional MR 
associations, but none showed strong evidence of colocalization (Supplementary Table 13) 
and little evidence of heterogeneity (Supplementary Table 14).  
 
Estimating protein effects on human phenotypes using pQTLs with heterogeneous effects 
across studies 
Among the 2,113 selected instruments, we checked whether the 1,062 instruments with 
association information in at least two studies showed consistent effect size across studies 
(Supplementary Table 15). For these SNPs, we found that 62 showed evidence of difference 




in effect size across studies (tier 2 instruments), for which we performed MR analyses using 
the most significant SNP across studies and report the findings with caution. Some proteins 
that are targets of approved drugs were found to have potential causal effects in this 
analysis, such as interleukin-6 receptor (IL6R) on rheumatoid arthritis (RA)34, and coronary 
heart disease (CHD)21 (Supplementary Table 16). Tocilizumab, a monoclonal antibody 
against IL6R, is used to treat RA, while canakinumab, a monoclonal antibody against 
interleukin-1 beta (an upstream inducer of interleukin-6), has been shown to reduce 
cardiovascular events specifically among patients who showed reductions in interleukin-635. 
As another test of heterogeneity across studies, where the same protein was 
measured in two or more studies, we performed colocalization analysis of each pQTL (in one 
study) against the same pQTL (in another study) for the two studies in which we had access 
to full summary results (Sun et al.9 and Folkersen et al.14). Of the 41 proteins measured in 
both studies, 76 pQTLs could be tested using conventional colocalization and PWCoCo 
(Supplementary Table 15). We found weak evidence of colocalization for 51 pQTLs 
(posterior probability < 0.8), which suggested either two different signals were present 
within the test region or the protein has a pQTL in one study but not in the other. In either 
case, as one of the two distinct signals may be genuine, we performed MR analysis of these 
25 pQTLs using instruments from each study separately. Eight associations had MR 
evidence, but only one showed colocalization evidence (IL27 levels on human height; 
Supplementary Table 17).  
 
Sensitivity analyses to evaluate reverse causality 
For potential associations between proteins and phenotypes identified in the previous 
analyses, we undertook two sensitivity analyses to highlight results due to reverse 
causation: bi-directional MR24 and Steiger filtering25 (Online Methods, Distinguishing causal 
effects from reverse causality). In general, we found little evidence of reverse causality for 
genetic predisposition to diseases on protein level changes (more details in Supplementary 
Note, Bi-directional MR and Steiger filtering results; Supplementary Data 1).  
 
Drug target prioritization and repositioning using phenome-wide MR 
Given that human proteins represent the major source of therapeutic targets, we sought to 
mine our results for targets of molecules already approved as treatments or in ongoing 
clinical development. We first compared MR findings for 1,002 proteins against 225 
phenotypes with historic data on progression of target-indication pairs in Citeline’s 
PharmaProjects (downloaded on 9th May 2018). Of 783 target-indication pairs with an 
instrument for the protein and association results for a phenotype similar to the indication 
for which the drug had been trialled, 9.2% (73 pairs) had successful (approved) drugs, 69.1% 
had failed drugs (including 195 failed drugs in the clinical stage and 354 drugs that failed in 
the preclinical stage) and 20.3% were for drugs still in development (161 pairs). The 268 
pairs for successful (73) or failed (195) drugs were included in further analyses 
(Supplementary Table 18). We observed eight target-indication pairs of successful drugs 
with MR and colocalization evidence of a potentially causal relationship between protein 
and disease (Supplementary Table 19). After removing duplicate genetic evidence for 
related indications for the same therapy (Online Methods, Drug target validation and 
repositioning), six successful drugs remained from 214 pairs (Supplementary Table 20). In 
addition to the PROC and IL6R examples discussed earlier, we found Proprotein convertase 
subtilisin/kexin type 9 (PCSK9) (target for evolocumab) for hypercholesterolemia and 




hyperlipidaemia, Angiotensinogen (AGT) for hypertension, IL12B for psoriatic arthritis and 
psoriasis, and TNF Receptor Superfamily Member 11a (TNFRSF11A) for osteoporosis. For 
each of these examples, the direction of effect between circulating protein and disease risk 
was consistent with the therapeutic mechanism, except IL6R and PROC at first sight. 
However, for IL6R and PROC, the alleles associated with higher soluble protein levels have 
been shown to also lead to lower intracellular pathway activation36,37, indicating consistency 
of direction with the therapeutic approach. These examples highlight the importance of 
careful examination of the biological mechanisms underlying plasma pQTLs to enable 
translation. Further removing associations potentially driven by protein-altering variants, as 
well as drugs that were in large part motivated by genetic evidence (e.g. PCSK9 fits both 
exclusion criteria), comparisons of the remaining 191 pairs indicated that protein-phenotype 
associations with MR and colocalization evidence remained more likely to become 
successful target-indication pairs (Table 1). Although we acknowledge the limited sample 
size of the test set, this raises enthusiasm for the utility of pQTL MR analyses with 
colocalization as a method for target prioritization.  
Previous efforts have highlighted the opportunities and challenges of using genetics 
for drug repositioning38. We identified three approved drugs for which we found pQTL MR 
and colocalization evidence for five phenotypes other than the primary indication and 23 
drug targets under development for 33 alternative phenotypes (Supplementary Table 21). 
An example of urokinase-type plasminogen activator (PLAU) levels associated with lower 
inflammatory bowel disease (IBD) risk is presented in the Supplementary Note (Case study 
for drug repurposing) and Supplementary Figure 8. 
We also evaluated drugs in current clinical trials and identified eight additional 
protein-phenotype associations with MR and colocalization evidence (Supplementary Table 
22), for which we observe MR evidence implicating an increased likelihood of success.  
Finally, we compared the 1,002 instrumentable proteins (i.e. those that passed our 
instrument selection procedure) against the druggable genome39, and found that 682 of the 
1,002 (68.1%) instrumentable proteins overlapped with the druggable genome 
(Supplementary Table 23 and Online Methods, Enrichment of proteome-wide MR with the 
druggable genome). We conducted a further enrichment analysis to assess the overlap 
between putative causal protein-phenotype associations and the druggable genome 
(Supplementary Table 24). Of the 295 top findings (120 proteins on 70 phenotypes) with 
both MR and colocalization evidence, 250 of them (87.7%) overlapped with the druggable 
genome (Fig. 5). This enrichment analysis will become more valuable with the continuous 
evolution of the druggable genome38. 
 





MR analysis of molecular phenotypes against disease phenotypes provides a promising 
opportunity to validate and prioritize novel or existing drug targets through prediction of 
efficacy and potential on-target beneficial or adverse effects40. Our phenome-wide MR 
study of the plasma proteome employed five pQTL studies to robustly identify and validate 
genetic instruments for thousands of proteins. We used these instruments to evaluate the 
potential effects of modifying protein levels on hundreds of complex phenotypes available 
in MR-Base23 in a hypothesis-free approach17. We confirmed that protein-phenotype 
associations with both MR and colocalization evidence predicted a higher likelihood of a 
particular target-indication pair being successful and highlight 283 potentially causal 
associations. Collectively, we underline the important role of pQTL MR analyses as an 
evidence source to support drug discovery and development and highlight a number of key 
analytical approaches to support such inference.  
In particular, we note the distinct opportunities and methodological requirements 
for MR of molecular phenotypes, such as transcriptomics and proteomics, compared to 
other complex exposures. For example, the number of instruments is often limited for 
proteins, restricting the opportunity to apply recently developed pleiotropy robust 
approaches27,41. New methods such as MR-robust adjusted profile scoring (MR-RAPS)42 
allow inclusion of many weak instruments in the MR analysis and have been applied to a 
recent proteome-wide MR study10. However, we note some examples where inclusion of 
multiple weaker instruments can reduce power and yield different results to those based on 
cis instruments alone40,43, and we note very limited additional gain from inclusion of trans 
instruments. A major advantage of proximal molecular exposures is the ability to include cis 
instruments (or interpretable trans instruments) with high biological plausibility, limiting the 
likelihood of horizontal pleiotropy22,44. Further, we note the limited gain from inclusion of 
trans instruments in our analysis. However, undue focus on single SNP MR approaches 
brings susceptibility to other pitfalls, such as the inability to examine heterogeneity of effect 
and to evaluate and remove potential epitope artefacts.  
To provide robust MR estimates for proteins, we note the important role of a 
number of sensitivity analyses following the initial MR in order to distinguish causal effects 
of proteins from those driven by horizontal pleiotropy, genetic confounding through LD45 
and/or reverse causation25. Of note, only two-thirds of our putative causal associations had 
strong evidence of colocalization, suggesting that a substantial proportion of the initial 
findings were likely to be driven by genetic confounding through LD between pQTLs and 
other disease-causal SNPs. To avoid misleading results, we suggest that for regions with 
multiple molecular trait QTLs, it is important to consider methods such as PWCoCo, which 
can avoid the assumptions of traditional colocalization approaches of just a single 
association signal per region46. In the current study, application of PWCoCo identified 
evidence of colocalization for 23 additional protein-phenotype associations hidden to 
marginal colocalization46. We note that recent recommendations support the use of 
colocalization as a follow up analysis to reduce false positives47.  
An important limitation of this work is that protein levels are known to differ 
between cell types48. In this study, we have estimated the role of protein measured in 
plasma on a range of complex human phenotypes but are unable to assess the relevance of 
protein levels in other tissues. While eQTL studies highlight a large proportion of eQTLs 
being shared across tissues37, there are many which show cell type and state specificity49, 
highlighting the potential value of applying the current approach to data from proteomics 




analyses in other cell types and tissues. We also hypothesize that, in instances with multiple 
conditionally distinct pQTLs but where we observe colocalization of only certain 
conditionally distinct pQTL-phenotype pairs, this may reflect underlying cell- and state-
specific heterogeneity in bulk plasma pQTLs, among which only certain cell-types or states 
are causal50. Although pQTL studies have not yet been performed as systematically across 
tissues or states as eQTL studies, it remains encouraging that our analyses using plasma 
proteins identify associations across a range of disease categories, including for psychiatric 
diseases for which we may expect key proteins to function primarily in the brain.  
Evaluating the potential of MR to inform drug target prioritization, we demonstrated 
that the presence of pQTL MR and colocalization evidence for a target-indication pair 
predicts a higher likelihood of approval. One of the limitations of our approach is the lack of 
comprehensive coverage of genetic data for all phenotypes for which drugs are in 
development, as well as our inability to instrument the entire proteome through pQTLs. As 
such, ongoing expansions in the scale, diversity and availability of GWAS will be important in 
providing more precise estimates of the value of MR and colocalization in drug target 
prioritization and in enabling its broader application.  
Another potential limitation of our work is the presence of epitope-binding artefacts 
driven by coding variants that may yield artefactual cis-pQTLs32. In particular, such instances 
may lead to false negative conclusions where, in the presence of a silent missense variant 
causing an artefactual pQTL but with no actual effect on protein function or levels, we do 
not correctly instrument the target protein. In instances where the missense variant appears 
to be driving the association with the phenotype, we suggest that causal inference may 
remain valid but inference on direction of association is challenged. Finally, the limited 
coverage of the proteome afforded by current technologies leaves the possibility of 
undetected pleiotropy of instruments. While cis-pQTLs are less likely to be prone to 
horizontal pleiotropy than trans-pQTLs, it is well known from studies of gene expression that 
cis variants can influence levels of multiple neighboring genes and hence the same is likely 
to be true for proteins. Future larger GWAS of the plasma proteome are likely to uncover 
many more variant-protein associations, increasing the apparent pleiotropy of many pQTLs.  
In conclusion, this study identified 283 putatively causal effects between the plasma 
proteome and the human phenome using the principles of MR and colocalization. These 
observations support, but do not prove, causality, as potential horizontal pleiotropy remains 
an alternative explanation. Our study provides both an analytical framework and an open 
resource to prioritize potential new targets and a valuable resource for evaluation of both 









We are extremely grateful to all the families who took part in the ALSPAC study, the 
midwives for their help in recruiting them, and the whole ALSPAC team, which includes 
interviewers, computer and laboratory technicians, clerical workers, research scientists, 
volunteers, managers, receptionists and nurses. We acknowledge Jack Bowden for statistical 
support and advice relating to MR-Egger regression.  
This publication is the work of the authors, and Jie Zheng will serve as guarantor for the 
contents of this paper. J.Z. is funded by a Vice-Chancellor Fellowship from the University of 
Bristol. This research was also funded by the UK Medical Research Council Integrative 
Epidemiology Unit (MC_UU_00011/1 and MC_UU_00011/4), GlaxoSmithKline, Biogen and 
the Cancer Research Integrative Cancer Epidemiology Programme (C18281/A19169). The UK 
Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of 
Bristol provide core support for ALSPAC. T.R.G. holds a Turing Fellowship with the Alan Turing 
Institute. A comprehensive list of grants funding is available on the ALSPAC website 
(http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). G.H. 
is funded by the Wellcome Trust and the Royal Society [208806/Z/17/Z]. M.V.H. is 
supported by a British Heart Foundation Intermediate Clinical Research Fellowship 
(FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical 
Research Centre. This study was funded/supported by the NIHR Biomedical Research Centre 
at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (GDS and 
TRG) [*]. This work was supported by the Elizabeth Blackwell Institute for Health Research, 
University of Bristol and the Medical Research Council Proximity to Discovery Award. P.E. is 
supported by CRUK [C18281/A19169]. S.L. is funded by the Bau Tsu Zung Bau Kwan Yeun 
Hing Research and Clinical Fellowship (200008682.920006.20006.400.01) from the 
University of Hong Kong. J.D. is funded by the National Institute for Health Research [Senior 
Investigator Award]. J.D. sits on the International Cardiovascular and Metabolic Advisory 
Board for Novartis (since 2010), the Steering Committee of UK Biobank (since 2011), the 
MRC International Advisory Group (ING) member, London (since 2013), the MRC High 
Throughput Science ‘Omics Panel Member, London (since 2013), the Scientific Advisory 
Committee for Sanofi (since 2013), the International Cardiovascular and Metabolism 
Research and Development Portfolio Committee for Novartis, and the Astra Zeneca 
Genomics Advisory Board (2018). P.C.H. is supported by CRUK Population Research 
Postdoctoral Fellowship C52724/A20138. 
Participants in the INTERVAL randomized controlled trial were recruited with the 
active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has 
supported field work and other elements of the trial. DNA extraction and genotyping was 
co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource 
(http://bioresource.nihr.ac.uk) and the NIHR [Cambridge Biomedical Research Centre at the 
Cambridge University Hospitals NHS Foundation Trust] [*]. The academic coordinating 
centre for INTERVAL was supported by core funding from: NIHR Blood and Transplant 
Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical 
Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; 
RG/18/13/33946) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge 
University Hospitals NHS Foundation Trust] [*]. A complete list of the investigators and 
contributors to the INTERVAL trial is provided in Di Angelantonio et al. (Lancet 390, 2360-
2371, 2017). The academic coordinating centre would like to thank blood donor centre staff 
and blood donors for participating in the INTERVAL trial. 




We gratefully acknowledge all studies and databases that have made their GWAS 
summary data available for this study: arcOGEN (Arthritis Research UK Osteoarthritis 
Genetics), BCAC (the Breast Cancer Association Consortium), C4D (Coronary Artery Disease 
Genetics Consortium), CARDIoGRAM (Coronary ARtery DIsease Genome wide Replication 
and Meta-analysis), CKDGen (Chronic Kidney Disease Genetics consortium), DIAGRAM 
(DIAbetes Genetics Replication And Meta-analysis), EAGLE (EArly Genetics and Lifecourse 
Epidemiology Consortium), EAGLE Eczema (EArly Genetics and Lifecourse Epidemiology 
Eczema Consortium), EGG (Early Growth Genetics Consortium), ENIGMA (Enhancing Neuro 
Imaging Genetics through Meta Analysis), GCAN (Genetic Consortium for Anorexia Nervosa), 
GEFOS (GEnetic Factors for OSteoporosis Consortium), GIANT (Genetic Investigation of 
ANthropometric Traits), GIS (Genetics of Iron Status consortium), GLGC (Global Lipids 
Genetics Consortium), GliomaScan (cohort-based genome-wide association study of glioma), 
GPC (Genetics of Personality Consortium), GUGC (Global Urate and Gout consortium), 
HaemGen (haemotological and platelet traits genetics consortium), IGAP (International 
Genomics of Alzheimer's Project), IIBDGC (International Inflammatory Bowel Disease 
Genetics Consortium), ILCCO (International Lung Cancer Consortium), IMSGC (International 
Multiple Sclerosis Genetic Consortium), ISGC (International Stroke Genetics Consortium), 
MAGIC (Meta-Analyses of Glucose and Insulin-related traits Consortium), MDACC (MD 
Anderson Cancer Center), MESA (Multi-Ethnic Study of Atherosclerosis), Neale’s lab (a team 
of researchers from Benjamin Neale’s group, who made the UK Biobank GWAS summary 
statistics publically available), OCAC (Ovarian Cancer Association Consortium), IPSCSG (the 
International PSC study group), NHGRI-EBI GWAS catalog (National Human Genome 
Research Institute and European Bioinformatics Institute Catalog of published genome-wide 
association studies), PanScan (Pancreatic Cancer Cohort Consortium), PGC (Psychiatric 
Genomics Consortium), Project MinE consortium, ReproGen (Reproductive ageing Genetics 
consortium), SSGAC (Social Science Genetics Association Consortium), TAG (Tobacco and 
Genetics Consortium), and UK Biobank.  
J.Z. acknowledges his grandmother ChenZhu for all her support, may she rest in 
peace.  
 
*The views expressed are those of the authors and not necessarily those of the NHS, the 
NIHR or the Department of Health and Social Care. 
 
Author contributions  
J.Z., V.H. and D.B. performed the Mendelian randomization analysis. J.Z. and D.B. performed 
the colocalization analysis. J.Z. performed the conditional analysis. V.H., Y.L., B.E., and T.R.G. 
developed the database and web browser. J.Z., V.W., and M.R.H. performed the drug target 
prioritization and enrichment analysis. J.Z. and R.S. conducted the druggable genome 
analysis. J.Z. and P.E. conducted the pathway and protein-protein interaction analysis. 
M.R.H., A.G., T.G.R., B.E., H.M.M., J.Y., C.L., S.L., and J.R. conducted supporting analyses. 
J.R.S., B.B.S., J.D., H.R., and J.C.M. provided key data and supported the MR analysis. M.R.H., 
J.Z.L., K.E., L.M., M.V.H., D.W., and M.R.N. reviewed the paper and provided key comments. 
J.Z., V.H., D.B., V.W., P.C.H., A.S.B., G.D.S., G.H., R.A.S., and T.R.G. wrote the manuscript. J.Z., 
T.R.G., and R.A.S. conceived and designed the study and oversaw all analyses. [AU: Please 
list the contribution(s) of Stephen Burgess.] 
 




Competing Interests Statement 
A.G., L.M., M.R.H., D.W., M.R.N., R.S., and R.A.S. are employees and shareholders in 
GlaxoSmithKline. H.R., J.Z.L., and K.E. are employees and shareholders in Biogen. J.Z and 
V.H. is employed on a grant funded by GlaxoSmithKline. D.B. is employed on a grant funded 
by Biogen. T.R.G., G.H., and G.D.S. receive funding from GlaxoSmithKline and Biogen for the 
work described here. A.S.B. has received grants from Merck, Novartis, Biogen, Pfizer and 
AstraZeneca. M.V.H. has collaborated with Boehringer Ingelheim in research, and in 
accordance with the policy of the Clinical Trial Service Unit and Epidemiological Studies Unit 
(University of Oxford), did not accept any personal payment. 
This work was supported by Health Data Research UK, which is funded by the UK 
Medical Research Council, Engineering and Physical Sciences Research Council, Economic 
and Social Research Council, Department of Health and Social Care (England), Chief Scientist 
Office of the Scottish Government Health and Social Care Directorates, Health and Social 
Care Research and Development Division (Welsh Government), Public Health Agency 







1. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through 
human genetics. Nat. Rev. Drug Discov. 12, 581–594 (2013). 
2. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical 
development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014). 
3. Arrowsmith, J. & Miller, P. Phase II and Phase III attrition rates 2011–2012. Nat. Rev. 
Drug Discov. 12, 569 (2013). 
4. Harrison, R. K. Phase II and phase III failures: 2013–2015. Nat. Rev. Drug Discov. 15, 
817 (2016). 
5. Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-development 
pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37 (2014). 
6. Nelson, M. R. et al. The support of human genetic evidence for approved drug 
indications. Nat. Genet. 47, 856–860 (2015). 
7. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts 
complex trait gene targets. Nat. Genet. 48, 481–487 (2016). 
8. Richardson, T. G. et al. Systematic Mendelian randomization framework elucidates 
hundreds of CpG sites which may mediate the influence of genetic variants on disease. 
Hum. Mol. Genet. 27, 3293–3304 (2018). 
9. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 
(2018). 
10. Chong, M. et al. Novel drug targets for ischemic stroke identified through Mendelian 
randomization analysis of the blood proteome. Circulation 140, 819–830 (2019). 
11. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 
16, 19–34 (2017). 
12. Imming, P., Sinning, C. & Meyer, A. Drugs, their targets and the nature and number of 
drug targets. Nat. Rev. Drug Discov. 5, 821–834 (2006). 
 
 
13. Suhre, K. et al. Connecting genetic risk to disease end points through the human blood 
plasma proteome. Nat. Commun. 8, 14357 (2017). 
14. Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in 
cardiovascular disease. PLoS Genet. 13, e1006706 (2017). 
15. Yao, C. et al. Genome-wide association study of plasma proteins identifies putatively 
causal genes, proteins, and pathways for cardiovascular disease. Nat. Commun. 9, 3268 
(2018). 
16. Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to 
disease. Science 361, 769–773 (2018). 
17. Evans, D. M. & Davey Smith, G. Mendelian randomization: new applications in the 
coming age of hypothesis-free causality. Annu. Rev. Genomics Hum. Genet. 16, 327–350 
(2015). 
18. Davey Smith, G. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology 
contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 
1–22 (2003). 
19. Zheng, J. et al. Recent developments in Mendelian randomization studies. Curr. 
Epidemiol. Rep. 4, 330–345 (2017). 
20. Millwood, I. Y. et al. Association of CETP gene variants with risk for vascular and 
nonvascular diseases among Chinese adults. JAMA Cardiol. 3, 34–43 (2018). 
21. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium et al. 
The interleukin-6 receptor as a target for prevention of coronary heart disease: a 
mendelian randomisation analysis. Lancet 379, 1214–1224 (2012). 
22. Swerdlow, D. I. et al. Selecting instruments for Mendelian randomization in the wake of 
genome-wide association studies. Int. J. Epidemiol. 45, 1600–1616 (2016). 
 
 
23. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the 
human phenome. Elife 7, e34408 (2018). 
24. Timpson, N. J. et al. C-reactive protein levels and body mass index: elucidating direction 
of causation through reciprocal Mendelian randomization. Int. J. Obes. 35, 300–308 
(2011). 
25. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between 
imprecisely measured traits using GWAS summary data. PLoS Genet. 13, e1007081 
(2017). 
26. Hemani, G. et al. Automating Mendelian randomization through machine learning to 
construct a putative causal map of the human phenome. bioRxiv (2017) 
doi:10.1101/173682. 
27. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary 
data Mendelian randomization. Stat. Med. 36, 1783–1802 (2017). 
28. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic 
association studies using summary statistics. PLoS Genet. 10, e1004383 (2014). 
29. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics 
identifies additional variants influencing complex traits. Nat. Genet. 44, 369–375 (2012). 
30. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple 
instrumental variables in Mendelian randomization: comparison of allele score and 
summarized data methods. Stat. Med. 35, 1880–1906 (2016). 
31. de Lange, K. M. et al. Genome-wide association study implicates immune activation of 
multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017). 
32. Solomon, T. et al. Identification of common and rare genetic variation associated with 
plasma protein levels using whole-exome sequencing and mass spectrometry. Circ. 
Genom. Precis. Med. 11, e002170 (2018). 
 
 
33. Taylor, F. B., Jr, Peer, G. T., Lockhart, M. S., Ferrell, G. & Esmon, C. T. Endothelial cell 
protein C receptor plays an important role in protein C activation in vivo. Blood 97, 
1685–1688 (2001). 
34. Hashizume, M. et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging 
therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. 
Int. Rev. Immunol. 34, 265–279 (2015). 
35. Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence 
rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab 
Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Heart J. 39, 3499–
3507 (2018). 
36. Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor 
signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, e1003444 
(2013). 
37. Stacey, D. et al. Elucidating mechanisms of genetic cross-disease associations: an 
integrative approach implicates protein C as a causal pathway in arterial and venous 
diseases. medRxiv (2020) doi:10.1101/2020.03.16.20036822. 
38. Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nat. 
Biotechnol. 30, 317–320 (2012). 
39. Finan, C. et al. The druggable genome and support for target identification and validation 
in drug development. Sci. Transl. Med. 9, eaag1166 (2017). 
40. Holmes, M. V., Ala-Korpela, M. & Smith, G. D. Mendelian randomization in 




41. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid 
instruments: effect estimation and bias detection through Egger regression. Int. J. 
Epidemiol. 44, 512–525 (2015). 
42. Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D. S. Statistical inference in two-
sample summary-data Mendelian randomization using robust adjusted profile score. 
aRxiv (2018).  
43. Evans, D. M. et al. Mining the human phenome using allelic scores that index biological 
intermediates. PLoS Genet. 9, e1003919 (2013). 
44. Timpson, N. J. One size fits all: are there standard rules for the use of genetic instruments 
in Mendelian randomization? Int. J. Epidemiol. 45, 1617–1618 (2016). 
45. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in 
Mendelian randomization studies. Hum. Mol. Genet. 27, R195–R208 (2018). 
46. Wu, Y. et al. Colocalization of GWAS and eQTL signals at loci with multiple signals 
identifies additional candidate genes for body fat distribution. Hum. Mol. Genet. 28, 
4161–4172 (2019). 
47. Wainberg, M. et al. Opportunities and challenges for transcriptome-wide association 
studies. Nat. Genet. 51, 592–599 (2019). 
48. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015). 
49. GTEx Consortium et al. Genetic effects on gene expression across human tissues. Nature 
550, 204–213 (2017). 
50. Kim-Hellmuth, S. et al. Genetic regulatory effects modified by immune activation 








Figure 1 | Study design of this phenome-wide MR study of the plasma proteome. The 
study included instrument selection and validation, outcome selection, four types of MR 
analyses, colocalization, sensitivity analyses, and drug target validation.   
 
Figure 2 | A demonstration of pairwise conditional and colocalization (PWCoCo) analysis. 
Assume there are two conditional independent association pQTL signals (SNP 1 and SNP 2) 
and two conditional independent outcome signals (SNP 1 and SNP 3) in the tested region. A 
naïve colocalization analysis using marginal association statistics will return weak evidence 
of colocalization (showed in regional plots A and D). By conducting the analyses conditioning 
on SNP 2 (plot B) and 1 (plot C) for the pQTLs and conditioning on SNP 1 (plot E) and 3 (plot 
F) for the outcome phenotype, each of the nine pairwise combinations of pQTL and 
outcome association statistics (represented as lines with different colors in the middle of 
this figure) will be tested using colocalization. In this case, the combination of plot B and 
plot E shows evidence of colocalization but the remaining eight do not.  
 
Figure 3 | Miami plot for the cis-only analysis, with circles representing the MR results for 
proteins on human phenotypes. The labels refer to top MR findings with colocalization 
evidence, with each protein represented by one label. The color refers to top MR findings 
with P < 3.09 x 10-7, where red refers to immune-mediated phenotypes, blue refers to 
cardiovascular phenotypes, green refers to lung-related phenotypes, purple refers to bone 
phenotypes, orange refers to cancers, yellow refers to glycemic phenotypes, brown refers to 
psychiatric phenotypes, pink refers to other phenotypes and grey refers to phenotypes that 
showed less evidence of colocalization. The x-axis is the chromosome and position of each 
MR finding in the cis region. The y-axis is the -log10 P value of the MR findings, MR findings 
with positive effects (increased level of proteins associated with increasing the phenotype 
level) are represented by filled circles on the top of the Miami plot, while MR findings with 
negative effects (decreased level of proteins associated with increasing the phenotype level) 
are on the bottom of the Miami plot.  
 
Figure 4 | Regional association plots of IL23R plasma protein level and Crohn’s disease in 
the IL23R region. a,b, Regional plots of IL23R protein level and Crohn’s disease without 
conditional analysis. Plot in b lists the sets of conditionally independent signals for Crohn’s 
disease in this region: rs7517847, rs7528924, rs183020189, rs7528804 (a proxy for the 
second IL23R hit rs3762318, r2 = 0.42 in the 1000 Genome Europeans) and rs11209026 (a 
proxy for the top IL23R hit rs11581607, r2 = 1 in the 1000 Genome Europeans), conditional P 
value < 1 x 10-7. c, Regional plot of IL23R with the joint SNP effects conditioned on the 
second hit (rs3762318) for IL23R. d, Regional plot of Crohn’s disease with the joint SNP 
effects adjusted for other independent signals except the top IL23R signal rs11581607. e, 
Regional plot of IL23R with the joint SNP effects conditioned on the top hit (rs11581607) for 
IL23R. f, Regional plot of Crohn’s disease with the joint SNP effects adjusted for other 
independent signals except the second IL23R signal rs3762318. The heatmap of the 
colocalization evidence for IL23R association on Crohn’s disease (CD) in the IL23R region is 




Figure 5 | Enrichment of phenome-wide MR of the plasma proteome with the druggable 
genome. In this figure, we only show proteins with convincing MR and colocalization 
evidence with at least one of the 70 phenotypes. The x-axis shows the categories of 70 
human phenotypes, where the phenotypes have been grouped into 8 categories: 8 
autoimmune diseases (red), 3 bone phenotypes (purple), 8 cancers (orange), 12 
cardiovascular phenotypes (blue), 4 glycemic phenotypes (yellow), 2 lung phenotypes 
(green), 4 psychiatric phenotypes (brown), and 29 other phenotypes (pink). The y-axis 
presents the tiers of the druggable genome (as defined by Finan et al.39) of 120 proteins 
under analysis, where the proteins have been classified into 4 groups based on their 
druggability: tier 1 contains 23 proteins that are efficacy targets of approved small 
molecules and biotherapeutic drugs, tier 2 contains 11 proteins closely related to approved 
drug targets or with associated drug-like compounds, tier 3 contains 58 secreted or 
extracellular proteins or proteins distantly related to approved drug targets, and 28 proteins 
have unknown druggable status (Unclassified). The cells with colors are protein-phenotype 
associations with strong MR and colocalization evidence. Cells in green are associations 
overlapping with the tier 1 druggable genome, while cells in yellow, red or purple were 
associations with tier 2, tier 3 or unclassified. More detailed information is shown in 
Supplementary Table 24. 




Table 1 | Enrichment analysis comparing target-indication pairs with or without MR and colocalization evidence 
 
 Mendelian randomization and colocalization evidence 
Target-indication pair approved  
after clinical trials 
 YES NO 
YES 4 40 
NO 0 147 
 
The protein-phenotype association pairs were grouped into four categories: (i) pairs with both MR/colocalization indications of causality and 
drug trial success; (ii) pairs with MR and colocalization evidence but no drug trial evidence; (iii) pairs with no strong MR or colocalization 
evidence but with drug trial evidence; and (iv) pairs with no strong MR, colocalization or drug trial evidence. The cut-off for MR evidence was P 
< 3.5 x 10-7; the cut off for colocalization evidence was posterior probability > 80%. The drug trial evidence was obtained from PharmaProjects 
database. The MR and colocalization analysis results involved in this analysis including both tier 1 and tier 2 instruments in both cis and trans 
region. More results comparing MR and trial evidence for cis-only and tier 1 instruments can be found in Supplementary Table 20. 
 





Instrument selection  
pQTLs from five GWAS9,13-16  were used for the instrument selection (Fig. 1). We first 
mapped SNPs to genome build GRCh37.p13 coordinates and then used the following criteria 
to select instruments:  
• We selected SNPs that were associated with any protein (using a P-value threshold ≤ 
5 x 10-8) in at least one of the five studies, including both cis and trans pQTLs.  
• Due to the complex LD structure of SNPs within the human Major Histocompatibility 
Complex (MHC) region, we removed SNPs and proteins coded for by genes within 
the MHC region (chr6: from 26 Mb to 34 Mb).  
• We then conducted linkage disequilibrium (LD) clumping for the instruments with 
the TwoSampleMR R package23 to identify independent pQTLs for each protein. We 
used r2 < 0.001 as the threshold to exclude dependent pQTLs in the cis (or trans) 
gene region. 
After instrument selection, 2,113 instruments were kept for further instrument validation 
(Supplementary Table 1). The instrument selection process, and the number of instruments 
for proteins at each step in the process, is illustrated in Figure 1. 
We incorporated conditionally distinct signals from protein association data through 
systematic conditional analysis. Of the five studies, Sun et al.9 reported conditionally distinct 
results for both cis and trans pQTLs, which have been used in our study. Folkersen et al.14 
have shared summary statistics, with which we performed approximate conditional analyses 
ourselves using GCTA-COJO29, with genotype data from mothers in the Avon Longitudinal 
Study of Parents and Children (ALSPAC) as the LD reference panel51,52 (a description of the 
ALSPAC cohort can be found in Supplementary Note, Description of ALSPAC study). 
Conditionally independent signals in the cis region for Sun et al. and Folkersen et al. are 
reported in Supplementary Table 5. 
 
Instrument validation 
For the 2,113 instruments, we further classified them into three groups (noted as tier 1, tier 
2 and tier 3 instruments) using two major instrument-filtering steps: a specificity test and a 
consistency test. More details of instrument validation, including harmonization of proteins 
and instruments and statistical tests for consistency can be found in the Supplementary 
Note (The protocol of the instrument validation). 
 
Test estimating instrument specificity 
Absence of horizontal pleiotropy is one of the core assumptions for MR. This assumes that 
the genetic variant should only be related to the outcome of interest through the 
instrumented exposure. We noted that some SNPs were associated with more than one 
protein. For example, APOE SNP rs7412 is associated with a set of proteins such as ADAM11, 
APBB2, and APOB. We plotted a histogram of the number of proteins each instrument was 
associated with (Supplementary Fig. 6) and considered instruments associated with more 
than 5 proteins as highly pleiotropic and assigned them as tier 3 instruments (which were 
excluded from all analyses). For instruments associated with fewer than (or equal to) five 
proteins, we reported the number of proteins each of them (and their proxies with LD r2 > 
0.5) was associated with to indicate the level of potential pleiotropy.  




To further distinguish vertical and horizontal pleiotropy for these instruments, we 
used biological pathway information from Reactome (https://reactome.org/) and protein-
protein interaction information from STRING DB (https://string-db.org/) implemented in 
EpiGraphDB (www.epigraphdb.org; Supplementary Note, Distinguishing vertical and 
horizontal pleiotropic instruments using biological pathway data). After this analysis, 68 
instruments associated with multiple proteins were mapped to the same pathway (or same 
PPI) and were considered as valid instruments. Given there are other pathways and PPIs 
that may be not included in Reactome and STRING, we kept tier 1 and 2 instruments 
associated with 1 to 5 proteins for the main MR analysis, but we recorded the number of 
proteins and number of pathways these instruments are associated with as an indication of 
potential pleiotropy. 
 
Consistency test estimating instrument heterogeneity across studies 
Among the 2,113 pQTLs selected as instruments, we looked up available protein GWAS 
results (Sun et al.9, Suhre et al.13 and Folkersen et al.14 with full GWAS summary statistics; 
Yao et al.15 and Emilsson et al.16 with pQTLs only) and found 1,062 pQTLs (or proxies with 
r2 > 0.8) with association information in at least two studies (Supplementary Table 15). We 
then tested the beta-beta correlation using the Pearson correlation function in R. The 
results of the beta-beta correlations of SNP effects for each pair of studies and the number 
of SNPs included in each correlation analysis can be found in Supplementary Table 2.  
We further performed two consistency tests on the instruments that were present 
across studies: (i) pairwise Z test; (ii) colocalization analysis of proteins across studies 
(details of the analyses in Supplementary Note, The protocol of the instrument validation). 
Instruments showing evidence of high heterogeneity across studies using either the pair-
wise Z test (pairwise Z > 5) or colocalization analysis (PP < 80%), were flagged as tier 2 
instruments. Recognizing that lack of replication and effect heterogeneity does not preclude 
at least one of these effects being genuine, we used these instruments separately for the 
follow-up genetic analyses (Supplementary Table 3) and reported the findings with caution.  
We designated instruments passing both pleiotropy and consistency tests as tier 1 
instruments and used them as primary instruments for the MR analysis.  
 
Identifying cis and trans instruments    
We further split tier 1 instruments into two groups: (i) cis-acting pQTLs within a 500-kb 
window from each side of the leading pQTL of the protein were used for the initial MR 
analysis (defined as the cis-only analysis)45; (ii) trans-acting pQTLs outside the 500-kb 
window of the leading pQTL were designated as trans instruments. While trans instruments 
may be more prone to pleiotropy, their inclusion could increase statistical power as well as 
the scope of downstream sensitivity analyses (e.g. tests for heterogeneity between 
instruments). Therefore, for the proteins with cis instruments, we also looked for additional 
trans instruments, and if these were available, we conducted further MR analyses using 
both sets of instruments (defined as the "cis + trans" analysis).  
For cis instruments, we looked up their predicted consequence via Variant Effect 
Predictor53 hosted by Ensembl. We identified coding variants (including missense, stop-
lost/gained, start-lost/gained and splice-altering variants) since epitope-binding artefacts 
driven by coding variants may yield artefactual cis pQTLs32. We then conducted a sensitivity 
MR analysis that excluded cis instruments that are in the coding region to further avoid the 
potential issue of epitope-binding artefacts driven by coding variants. 






We obtained effect estimates for the association of the pQTLs with complex human 
phenotypes using GWAS summary statistics that were included in the MR-Base database 
(http://www.mrbase.org). We selected GWAS with the greatest excepted statistical power 
when multiple GWAS records for the same phenotype were available in MR-Base. Diseases 
were defined as primary outcomes. Risk factors were defined as secondary outcomes. After 
selection, 153 diseases and 72 risk factors (such as lipids and glucose phenotypes) were 
included as outcomes for the MR analyses (Supplementary Table 6).  
 
Causal inference and sensitivity analyses  
The following sections describe the two-sample MR analyses using single or small numbers 
of instruments on 153 diseases and 72 risk factors. To identify possible violations of 
assumptions of MR and to distinguish between the aforementioned scenarios in 
Supplementary Figure 3, we therefore conducted the following sensitivity analyses: 
colocalization analysis28, tests for heterogeneity between instrumental SNPs27, bi-directional 
MR24, and Steiger filtering25,26 (Fig. 1).  
 
Estimating the causal effects of proteins on human phenotypes using MR 
In the initial MR analysis, proteins were treated as the exposures and 225 complex human 
phenotypes as the outcomes (Fig. 1, Estimate putative causal relationship). Due to high 
correlation among some of the tested phenotypes (e.g. coronary heart disease (CHD) and 
myocardial infarction), we used the PhenoSpD method54,55 to provide a more appropriate 
estimate of the number of independent tests. We selected a P-value threshold of 0.05, 
corrected for the number of independent tests, as our threshold for prioritizing MR results 
for follow up analyses (number of tests = 142,857; P < 3.5 x 10-7). 
 
MR analysis using single locus instruments 
First, the strongest cis pQTL variants for each protein were used as the instrumental variable 
(described as ‘single cis’ analysis). The Wald ratio56 method was used to obtain MR effect 
estimates. In this analysis, the MR effect estimates were sensitive to the particular choice of 
pQTLs, since only the most strongly associated SNPs within each genomic region were used 
as instruments. Burgess et al. recently suggested that more precise causal estimates can be 
obtained using multiple genetic variants from a single gene region, even if the variants are 
correlated30,57. We used multiple conditional independent cis SNPs (Supplementary Table 5) 
against all 225 phenotypes to further evaluate the MR findings from our initial MR analysis 
(described as ‘multiple cis’ analysis). A generalized inverse variance weighted (IVW) model 
considering the LD pattern between the multiple cis SNPs was used to estimate the MR 
effects, where the pairwise LD (r2) were obtained from the 1000 Genomes European 
ancestry reference samples.  
 
MR analysis using multi-locus instruments 
Among the measured proteins reported in Sun et al.9, 34% had both cis and trans pQTLs and 
30% had only trans pQTLs. We also conducted MR on proteins with both cis and trans pQTLs 
(noted as the cis + trans MR analysis) and proteins with only trans pQTLs (noted as trans-
only analysis). In the cis + trans MR analysis, we tested the protein-phenotype associations 
of 66 proteins with both cis and trans instruments. The IVW method was used to obtain MR 




effect estimates. In the trans-only MR analysis, we used 351 trans instruments for 298 
proteins. The IVW method was used when two or more trans instruments were included in 
the analysis, whereas the Wald ratio method was used when only one trans instrument was 
included in the analysis.  
 
MR analysis software 
The majority of MR analyses (including Wald ratio, IVW, bi-directional MR, MR Steiger 
filtering and heterogeneity test across multiple instruments) were conducted using the MR-
Base TwoSampleMR R package (github.com/MRCIEU/TwoSampleMR)23. The IVW analysis 
considering LD pattern was conducted using the MendelianRandomization R package58. The 
MR results were plotted as forest plots and Miami plots using code derived from the ggplot2 
package in R. 
 
Distinguishing causal effects from genomic confounding due to linkage disequilibrium 
Results that survived the multiple testing threshold in the MR analysis were evaluated using 
a stringent Bayesian model (colocalization analysis) to estimate the posterior probability 
(PP) of each genomic locus containing a single variant affecting both the protein and the 
phenotype28. For protein and phenotype GWAS lacking sufficient SNP coverage or missing 
key information (e.g. allele frequency or effect size), we conducted the “LD check” analysis 
(more details of the two methods in Supplementary Note, Linkage disequilibrium check).  
 
Pairwise conditional and colocalization analysis  
The presence of multiple conditionally distinct association signals within the same genomic 
region will influence the performance of colocalization analysis. We therefore developed an 
analysis pipeline to integrate conditional and colocalization approaches for regions with 
multiple conditionally independent pQTLs. Where there was convincing MR evidence below 
the P-value threshold of 3.5 x 10-7, but no good evidence of colocalization using the marginal 
SNP effects of the exposures and outcomes (in total 148 MR associations in both cis and 
trans regions), we performed pairwise colocalization analyses of all conditionally distinct 
pQTLs against all identified conditionally distinct association signals in the outcome data 
(noted as pair-wise conditional and colocalization analysis: PWCoCo). The conditional 
analysis for proteins and human phenotypes was conducted using the GCTA-COJO 
package29, with genotype data from mothers in the Avon Longitudinal Study of Parents and 
Children (ALSPAC) as the LD reference panel51,52 (a description of the ALSPAC cohort can be 
found in Supplementary Note, Description of ALSPAC study). Figure 2 demonstrates the 
nine possible pair-wise combinations of various conditional signals for proteins and 
phenotypes at which there are two independent signals in the region (Supplementary Table 
27).  
For protein-phenotype associations that only showed colocalization evidence after 
we applied PWCoCo, we recorded the PWCoCo model that showed colocalization evidence 
in a new column “PWCoCo_model”, in Supplementary Tables 7, 8, 11, 12, 13, 16 and 17. 
 
Heterogeneity test and directionality test of MR findings 
For MR analyses using two or more instruments, we conducted heterogeneity tests to 
estimate the variability in the causal estimates obtained for each SNP (i.e. how consistent is 
the causal estimate across all SNPs used as separate instruments) (Fig. 1, Consistency of the 
causal estimate across all SNPs). Cochran’s Q test statistic was calculated for the IVW 




analyses, which is expected to be chi-squared distributed with number of SNPs minus one 
degrees of freedom27. Lower heterogeneity suggests a lower chance of violations of 
assumptions in MR estimates, such as the presence of confounding through horizontal 
pleiotropy59. 
In order to mitigate the potential impact of reverse causality (i.e. the hypothesised 
outcome actually has a causal effect on the hypothesised exposure and not vice versa), we 
used two approaches to identify directions of causality: bi-directional MR and Steiger 
filtering (more details in Supplementary Note, Directionality test). 
 
Drug target validation and repositioning  
Approved drug targets have previously been shown to be enriched for gene-phenotype 
associations6. We therefore wished to assess whether approved drug targets were enriched 
for protein-phenotype associations, as obtained in the present study using MR. We assessed 
the support for approved drug targets among our MR findings using Fisher’s exact test. 
Target-indication pairs for successful and failed drugs were identified using a manually 
annotated version of PharmaProjects database from Citeline 
(https://pharmaintelligence.informa.com/). The phenotypes used in the MR analyses and 
the indications listed in Citeline’s PharmaProjects (downloaded on 9th May 2018) were then 
manually mapped to MeSH headings as a common ontology. This allowed us to match the 
protein-phenotype associations with corresponding target-indication pairs. To improve this 
matching, we implemented a similarity matrix, derived from all MeSH headings in the 
manual mapping, and retained matches with a relative similarity greater than 0.7 for our 
analyses (the similarity matrix has been previously described in Nelson et al.6). We then 
compared whether the target-indication pair represented a successful or failed drug against 
whether there was a signal or not for the corresponding protein-phenotype pair among our 
MR findings. For the purposes of this test, a signal was defined as an MR result with P < 3.5 x 
10-7 (which is the Bonferroni P-value threshold of the MR analysis) with supporting evidence 
from colocalization analysis. We further conducted a set of sensitivity analyses based on the 
following criteria to increase the reliability of the enrichment analysis:  
1. We checked the direction of effect of MR findings and drug trial results for the eight 
approved drugs using therapeutic direction information from PharmaProjects. 
2. For target-indication pairs linked to similar phenotypes (for example, the same 
target associated with angina and myocardial infarction), we removed one of them 
to avoid double counting the same association.  
3. To avoid the influence of epitope-binding artefacts, we removed MR results 
estimated using missense variants as an instrument.   
4. We checked whether approved drugs had been motivated by genetics from Drug 
Bank (https://www.drugbank.ca/), which may have inflated the OR estimate.  
In total, we removed 75 target-indication pairs based on criteria 2 (45 pairs), 3 (23 pairs) and 
4 (2 pairs; some pairs appeared in multiple situations) and conducted the comparison 
between protein-phenotype associations using MR and target-indication pairs from 
PharmaProjects, both on each criterion separately and on all criteria together 
(Supplementary Table 20). 
Phenome-wide MR has demonstrated the potential to validate, repurpose and 
predict on-target side effects of drug targets. Of the protein-phenotype associations that 
showed evidence of colocalization identified in the cis-only, cis+trans, trans-only or MR 
analyses using pQTLs with heterogeneous effects across studies (noted as tier 2 




instruments), we first looked up how many proteins with MR evidence were established 
drug targets in the Informa PharmaProjects database. We then looked up how many of the 
associations were established target-indication pairs in the PharmaProjects database. More 
importantly, we predicted the potential adverse effects and repositioning opportunities of 
all marketed drugs and drugs under development using phenome-wide MR.  
 
Enrichment of proteome-wide MR with the druggable genome  
Previously, Finan et al.39 systematically identified 4479 genes as the newest druggable 
genome compendium. This study stratified the druggable genome set into three tiers. Tier 1 
(1,427 genes) included efficacy targets of approved small molecules and biotherapeutic 
drugs, as well as targets modulated by clinical-phase drug candidates; tier 2 was composed 
of 682 genes encoding proteins closely related to drug targets, or with associated drug-like 
compounds; and tier 3 contained 2,370 genes encoding secreted or extracellular proteins, 
distantly related proteins to approved drug targets, and members of key druggable gene 
families not already included in tier 1 or tier 2. We assessed whether the 1,002 proteins we 
selected for the MR analyses overlapped with the 4,479 genes from the druggable genome 
(Supplementary Table 23). The proteins were mapped based on the HGNC name of the 
encoding genes. We further assessed the overlap based on whether the protein had cis or 
trans instruments and based on the druggable genome tiers.  
In addition to the above comparison between instrumentable and druggable 
genome, we also assessed the enrichment of top pQTL MR findings with the druggable 
genome. 295 protein-phenotype associations (120 proteins on 70 phenotypes) with both 
MR and colocalization evidence were selected for this analysis. We stratified the 120 
proteins into 4 groups based on their druggability: tier 1 contained 23 proteins, tier 2 
contained 11 proteins, tier 3 contained 58 proteins, and 28 proteins remained unclassified. 
The 70 phenotypes were stratified into 8 groups: 8 autoimmune diseases, 3 bone 
phenotypes, 8 cancer phenotypes, 12 cardiovascular phenotypes, 4 glycemic phenotypes, 2 
lung phenotypes, 4 psychiatric phenotypes and 29 other phenotypes. The protein-
phenotype associations with MR and colocalization evidence were colored separately based 
on their druggability tiers. More details of this enrichment analysis are shown in Figure 5 
and Supplementary Table 24. 
 
Data availability 
The data (GWAS summary statistics) used in the analyses described here are freely 
accessible in the MR-Base platform (www.mrbase.org). All our analysis results for 989 
proteins against 225 human phenotypes are freely available to browse, query and download 
in EpiGraphDB (http://www.epigraphdb.org/pqtl/). An application programming interface 
(API) and R package documented on the website enable users to programmatically access 
data from the database. 
 
Code availability 
The code used in the Mendelian randomization and colocalization analyses described here 
are freely accessible via our GitHub repo (https://github.com/MRCIEU/epigraphdb-pqtl). 
The MR analysis was conducted using TwoSampleMR R package 
(https://github.com/MRCIEU/TwoSampleMR). We implemented the colocalization analysis 
using the coloc R package (created by Chris Wallace et al.), which can be downloaded here 
(https://cran.r-project.org/web/packages/coloc/index.html).  
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